Related Experiment Video
Updated: Jun 23, 2025
Creation of a Knee Joint-on-a-Chip for Modeling Joint Diseases and Testing Drugs
Published on: January 27, 2023
CRISPR-mediated Sox9 activation and RelA inhibition enhance cell therapy for osteoarthritis
Lan Zhao1, Yumei Lai1, Hongli Jiao1
1Department of Orthopedic Surgery, Rush University Medical Center, Chicago, IL, USA.
Abstract:
Osteoarthritis (OA) is a painful and debilitating disease affecting over 500 million people worldwide. Intraarticular injection of mesenchymal stromal cells (MSCs) shows promise for the clinical treatment of OA, but the lack of consistency in MSC preparation and application makes it difficult to further optimize MSC therapy and to properly evaluate the clinical outcomes. In this study, we used Sox9 activation and RelA inhibition, both mediated by the CRISPR-dCas9 technology simultaneously, to engineer MSCs with enhanced chondrogenic potential and downregulated inflammatory responses. We found that both Sox9 and RelA could be fine-tuned to the desired levels, which enhances the chondrogenic and immunomodulatory potentials of the cells. Intraarticular injection of modified cells significantly attenuated cartilage degradation and palliated OA pain compared with the injection of cell culture medium or unmodified cells. Mechanistically, the modified cells promoted the expression of factors beneficial to cartilage integrity, inhibited the production of catabolic enzymes in osteoarthritic joints, and suppressed immune cells. Interestingly, a substantial number of modified cells could survive in the cartilaginous tissues including articular cartilage and meniscus. Together, our results suggest that CRISPR-dCas9-based gene regulation is useful for optimizing MSC therapy for OA.
Insights
CRISPR-dCas9 technology enhances mesenchymal stromal cells (MSCs) for osteoarthritis (OA) treatment. Modified MSCs reduce cartilage damage and pain by improving chondrogenesis and reducing inflammation, offering a promising therapy for OA patients.
Area of Science:
- Biotechnology
- Regenerative Medicine
- Gene Editing
Background:
- Osteoarthritis (OA) affects over 500 million people globally, causing pain and disability.
- Mesenchymal stromal cells (MSCs) show therapeutic potential for OA via intraarticular injection.
- Current MSC therapy for OA faces challenges in preparation consistency and outcome evaluation.
Purpose of the Study:
- To engineer MSCs with improved chondrogenic and anti-inflammatory properties using CRISPR-dCas9 technology.
- To investigate the efficacy of modified MSCs in an OA model.
- To elucidate the mechanisms underlying the therapeutic effects of engineered MSCs.
Main Methods:
- Simultaneous CRISPR-dCas9-mediated Sox9 activation and RelA inhibition in MSCs.
- Intraarticular injection of engineered MSCs into an OA animal model.
- Assessment of cartilage degradation, OA pain, cell survival, and molecular mechanisms.
Main Results:
- Engineered MSCs exhibited enhanced chondrogenic and immunomodulatory potentials.
- Intraarticular injection of modified MSCs significantly reduced cartilage degradation and OA pain.
- Modified MSCs promoted cartilage-protective factors, inhibited catabolic enzymes, and suppressed immune cells.
- A significant number of modified MSCs survived in cartilaginous tissues post-injection.
Conclusions:
- CRISPR-dCas9-based gene regulation is an effective strategy for optimizing MSCs for OA therapy.
- Engineered MSCs demonstrate enhanced therapeutic efficacy and survival in OA joints.
- This approach offers a pathway to more consistent and effective MSC-based treatments for osteoarthritis.
Related Concept Videos
02:31Homologous Recombination
01:59CRISPR